Literature DB >> 11251387

DNA vaccination against La Crosse virus.

J Pavlovic1, J Schultz, H P Hefti, T Schuh, K Mölling.   

Abstract

For the development of effective conventional vaccines or DNA vaccines against viruses, the availability of suitable animal models is an essential prerequisite. For many recently emerging zoonotic viruses, suitable animal models are still missing. We have established a novel small animal model for DNA vaccines using mice lacking a functional interferon-alpha/beta receptor (IFNAR-1). IFNAR-1-deficient mice are highly susceptible to many different viruses despite their ability to mount a normal humoral and cellular immune response. Taking advantage of this animal model, we show that mice can be completely protected from lethal challenge with a single injection of plasmid DNA encoding the viral envelope proteins G1 and G2. By contrast, vaccination with a plasmid encoding the internal nucleocapsid protein N had little effect. In an effort to enhance the protective immune response to N we assessed the efficacy of vaccination with plasmid DNA encoding N in combination with a plasmid encoding the cytokine IL-12 as adjuvant. IL-12 enhanced the survival of mice following viral challenge, but the effect was independent of N indicating the involvement of components of the innate immune system such as NK cells. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11251387     DOI: 10.1159/000053999

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  7 in total

1.  An Overview of La Crosse Virus Disease.

Authors:  Elizabeth Matthews; Lakshmi Chauhan; Amanda L Piquet; Kenneth L Tyler; Daniel M Pastula
Journal:  Neurohospitalist       Date:  2022-02-28

2.  Age-dependent myeloid dendritic cell responses mediate resistance to la crosse virus-induced neurological disease.

Authors:  Katherine G Taylor; Tyson A Woods; Clayton W Winkler; Aaron B Carmody; Karin E Peterson
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

Review 3.  Innate immune response to La Crosse virus infection.

Authors:  Katherine G Taylor; Karin E Peterson
Journal:  J Neurovirol       Date:  2013-07-12       Impact factor: 2.643

4.  The CARD9-Associated C-Type Lectin, Mincle, Recognizes La Crosse Virus (LACV) but Plays a Limited Role in Early Antiviral Responses against LACV.

Authors:  João T Monteiro; Kathleen Schön; Tim Ebbecke; Ralph Goethe; Jürgen Ruland; Wolfgang Baumgärtner; Stefanie C Becker; Bernd Lepenies
Journal:  Viruses       Date:  2019-03-26       Impact factor: 5.048

5.  Recombinant hemagglutinin of swine H1N1 influenza virus expression in the insect cells: Formulation in Montanide ISA71 adjuvant and the potency studies.

Authors:  Sara Zahmati; Morteza Taghizadeh; Setareh Haghighat; Reza Jalalirad; Mehdi Mahdavi
Journal:  Iran J Basic Med Sci       Date:  2021-11       Impact factor: 2.699

6.  Differences in neuroinvasion and protective innate immune pathways between encephalitic California Serogroup orthobunyaviruses.

Authors:  Alyssa B Evans; Clayton W Winkler; Karin E Peterson
Journal:  PLoS Pathog       Date:  2022-03-04       Impact factor: 6.823

Review 7.  Throw out the Map: Neuropathogenesis of the Globally Expanding California Serogroup of Orthobunyaviruses.

Authors:  Alyssa B Evans; Karin E Peterson
Journal:  Viruses       Date:  2019-08-29       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.